AMD progresses through several stages, usually starting with dry AMD, which is the more common form of the condition. It advances to geographic atrophy (GA) in some cases. Both conditions damage ...
Symptoms vary though as there are two types of AMD: dry AMD and wet AMD. "Dry AMD is very common with about 80% of people with AMD having this form," says Dr. Purnima Patel, an ophthalmologist at ...
PST-611 is a first in class non-viral vectorized therapy for the treatment of dry age-related macular degeneration (AMD)/geographic atrophy (GA), expressing human transferrin, a highly potent iron ...
It involved confirming the therapeutic potential of SBL03 in the treatment of geographic atrophy, a severe form of age-related macular degeneration (dry AMD) using a groundbreaking, non-invasive ...
Shares in US biotech Iveric Bio have shot up after the company said its lead drug Zimura had slowed eyesight deterioration in patients with the dry form of age-related macular degeneration (AMD ...
The pharmaceutical industry is increasingly focused on developing pathway-based therapies for dry AMD, with promising treatments like ALK-001 and LBS-008 in trials, though a combination approach ...
PST-611 is a first-in-class non-viral vectorized therapy for the treatment of dry AMD/GA, expressing human transferrin, a highly potent iron regulator, to restore normal iron homeostasis.
PulseSight Therapeutics Announces First Close of its Series A Financing to Fund Clinical Development of PST-611 in dry AMD PulseSight Therapeutics S.A.S Thu, Feb 13, 2025, 3:00 AM 3 min read ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results